NGNE

Neurogene Inc.

NGNE · CIK 1404644 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$1M
20172024
Net Income−$75M
20172024
Operating CF−$71M
20172024
Free Cash Flow−$71M
20172024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Revenue$0.0B————$0.0B$0.0B—
Cost of Revenue————————
Gross Profit————————
R&D Expense$0.1B$0.0B$0.0B———$0.0B$0.0B
SG&A Expense————————
Operating Income$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B$-0.1B$-0.0B—
Net Income$-0.1B$0.0B$-0.1B$-0.1B$-0.0B$-0.1B$-0.0B$-0.1B
EPS (Basic)$-4.28$27.76$-1.04$-1.10————
EPS (Diluted)$-4.28$2.93$-1.04$-1.10————

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Total Assets$0.3B$0.2B$0.1B$0.2B$0.2B$0.1B$0.1B$0.1B
Current Assets$0.3B$0.2B$0.1B$0.1B$0.2B$0.1B$0.1B$0.1B
Cash & Equivalents$0.1B$0.1B$0.0B$0.1B$0.2B$0.1B$0.1B$0.1B
Total Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.3B$0.2B$0.1B$0.1B$0.2B$0.1B$0.1B$0.1B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Operating Cash Flow$-0.1B$-0.1B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B—
Investing Cash Flow$-0.1B$0.0B$-0.1B$-0.0B$-0.0B$-0.0B$0.1B—
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.2B$0.1B$0.0B$0.0B$0.1B$0.1B$0.0B—
← Companies